Señales en vivo de ARAV | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 ene 2024 @ 16:00):

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States...

Stats
Volumen de hoy	4.04M
Volumen promedio	2.24M
Capitalización de mercado	2.95M
EPS	$0 ( 2024-03-20 )
Próxima fecha de ganancias	( $0 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0528
ATR14	$0.0130 (32.42%)

Insider Trading

Date	Person	Action	Amount	type
2023-04-10	Petrini Maria Carolina	Buy	400 000	Nonqualified Stock Option (Right to Buy)
2023-04-10	Petrini Maria Carolina	Buy	0
2023-02-01	Mcintyre Gail Frances	Buy	700 000	Stock Option (Right to Buy)
2023-02-01	Geller Robert B.	Buy	400 000	Stock Option (Right to Buy)
2023-02-01	Howard Rudy	Buy	400 000	Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 91 transactions
Buy: 72 486 477 \| Sell: 119 333

Volumen Correlación

Largo: 0.29 (neutral)

Corto: 0.00 (neutral)

Signal:(20.648) Neutral

Aravive Inc Correlación

10 Correlaciones Más Positivas
MBIO	0.891
YVR	0.891
POAI	0.885
MPAA	0.881
CASA	0.874
ARIZ	0.871
ACOR	0.87
ARVL	0.867
AUBN	0.866
ALXN	0.865

10 Correlaciones Más Negativas
GRIN	-0.898
PPTA	-0.888
MOTNU	-0.882
ABIO	-0.881
GALT	-0.879
SMTC	-0.879
CATB	-0.877
CADL	-0.876
SGRP	-0.87
FISV	-0.868

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aravive Inc Correlación - Moneda/Commodity

-0.07
( neutral )

-0.57
( weak negative )

0.00
( neutral )

0.04
( neutral )

-0.48
( neutral )

0.67
( moderate )

Aravive Inc Finanzas

Annual	2022
Ingresos:	$9.14M
Beneficio Bruto:	$-57.80M (-632.60 %)
EPS:	$-2.22

FY	2022
Ingresos:	$9.14M
Beneficio Bruto:	$-57.80M (-632.60 %)
EPS:	$-2.22

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-2.48

FY	2020
Ingresos:	$5.69M
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-1.930

Financial Reports:

No articles found.

Aravive Inc

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

Actualizaciones en tiempo real para Aravive Inc [ARAV]

Upcoming Earnings Alert